Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | HRH2 | P25021 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573206 | 0.96 | CXCR4 (0.53) | CXCR4SIGMAR1CYP1A2HRH2HRH1 | |
| SCHEMBL3573043 | 0.94 | CYP1A2 (0.46) | CXCR4SIGMAR1CYP1A2HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL7417518 | 0.92 | CYP1A2 (0.44) | CXCR4SIGMAR1CYP1A2HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL16527966 | 0.92 | CYP1A2 (0.44) | CXCR4SIGMAR1CYP1A2HRH2HRH1 | |
| SCHEMBL3573381 | 0.89 | HRH2 (0.46) | CXCR4SIGMAR1CYP1A2HRH2HRH1 | |
| SCHEMBL687467 | 0.88 | CXCR4 (0.44) | CXCR4SIGMAR1HRH2HRH1L3MBTL1 | |
| SCHEMBL4446110 | 0.88 | CXCR4 (0.51) | CXCR4SIGMAR1HRH2HRH1TSHR | |
| SCHEMBL7418407 | 0.88 | HRH2 (0.45) | CXCR4SIGMAR1CYP1A2HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL7421188 | 0.88 | HRH2 (0.45) | CXCR4SIGMAR1CYP1A2HRH2HRH1 | |
| SCHEMBL3422198 | 0.88 | HRH2 (0.45) | CXCR4SIGMAR1CYP1A2HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683168-B2 | Compositions of novel opioid compounds and method of use thereof | Mount Cook Bio Sciences, Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-1874315-A2 | COMPOSITIONS OF NOVEL OPIOID COMPOUNDS AND METHOD OF USE THEREOF | Mount Cook Biosciences, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070043028-A1 | Compositions of novel opioid compounds and method of use thereof | DMK PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
| WO-2006113468-A2 | COMPOSITIONS OF NOVEL OPIOID COMPOUNDS AND METHOD OF USE THEREOF | MOUNT COOK BIOSCIENCES, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043028-A1 | Compositions of novel opioid compounds and method of use thereof | OPRL1, OPRD1, OPRK1 | CXCR4 1534/4885SIGMAR1 5/4885CYP1A2 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.